Coronary artery disease severity modifies associations between glycemic control and both mortality and myocardial infarction

Journal of Diabetes and Its Complications
Sridharan RaghavanThomas M Maddox

Abstract

This study examined whether the association between hemoglobin A1c (HbA1c) and short-term clinical outcomes is moderated by CAD severity. We studied 17,394 US Veterans with type 2 diabetes who underwent elective cardiac catheterization between 2005 and 2013. CAD severity was categorized as obstructive, non-obstructive, or no CAD. Using multivariable Cox proportional hazards regression, we assessed associations between time-varying HbA1c and two-year all-cause mortality and non-fatal MI, with an interaction term between HbA1c and CAD severity. 61%, 22%, and 17% of participants had obstructive, non-obstructive, and no CAD, respectively. CAD severity modified the relationship between HbA1c and each outcome (interaction p-value 0.0005 for mortality and <0.0001 for MI). Low HbA1c (<42 mmol/mol) was associated with increased mortality, relative to HbA1c of 48-52 mmol/mol, in individuals with obstructive CAD (HR 1.52 [1.17, 1.97]) and non-obstructive CAD (HR 2.61 [1.61, 4.23]), but not in those with no CAD (HR 0.91 [0.46, 1.79]). In contrast, higher HbA1c levels (≥53 mmol/mol) were associated with increased MI risk only in individuals with obstructive CAD. The associations between HbA1c and mortality and MI were moderated by CAD sever...Continue Reading

References

Sep 24, 2004·Annals of Internal Medicine·Elizabeth SelvinSherita Hill Golden
Jan 3, 2006·Journal of the American College of Cardiology·Roldano ScognamiglioAngelo Avogaro
Jun 20, 2007·Annals of Internal Medicine·Edward W GreggCatherine C Cowie
Jun 10, 2008·The New England Journal of Medicine·UNKNOWN Action to Control Cardiovascular Risk in Diabetes Study GroupWilliam T Friedewald
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Jun 9, 2009·The New England Journal of Medicine·UNKNOWN BARI 2D Study GroupBurton E Sobel
Mar 12, 2010·The New England Journal of Medicine·Manesh R PatelPamela S Douglas
Oct 12, 2010·The New England Journal of Medicine·Sophia ZoungasUNKNOWN ADVANCE Collaborative Group
Dec 20, 2011·Diabetes Care·Elizabeth R SeaquistUNKNOWN ACCORD Investigators
Aug 1, 2013·BMJ : British Medical Journal·Atsushi GotoMitsuhiko Noda
Dec 11, 2013·JAMA Internal Medicine·Chin-Lin TsengLeonard M Pogach
Apr 18, 2014·The New England Journal of Medicine·Edward W GreggLinda Geiss
Sep 23, 2014·The New England Journal of Medicine·Sophia ZoungasUNKNOWN ADVANCE-ON Collaborative Group
Nov 5, 2014·JAMA : the Journal of the American Medical Association·Thomas M MaddoxJohn S Rumsfeld
Jan 13, 2015·JAMA Internal Medicine·Kasia J LipskaMichael A Steinman
Jun 4, 2015·The New England Journal of Medicine·Rodney A HaywardUNKNOWN VADT Investigators
Sep 5, 2015·Current Diabetes Reports·Alice P S Kong, Juliana C N Chan
Sep 16, 2015·Diabetes & Metabolism Journal·Jae Seung YunYu Bae Ahn
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Dec 18, 2015·The Journal of Clinical Endocrinology and Metabolism·Aaron LeongJames B Meigs
Jun 9, 2016·JAMA Internal Medicine·Rozalina G McCoyNilay D Shah
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Dec 17, 2016·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.